Literature DB >> 12449499

Bayesian analysis of population PK/PD models: general concepts and software.

David J Lunn1, Nicky Best, Andrew Thomas, Jon Wakefield, David Spiegelhalter.   

Abstract

Markov chain Monte Carlo (MCMC) techniques have revolutionized the field of Bayesian statistics by enabling posterior inference for arbitrarily complex models. The now widely used WinBUGS software has, over the years, made the methodology accessible to a great many applied scientists, in all fields of research. Despite this, serious application of MCMC methods within the field of population PK/PD has been comparatively limited. We appreciate that for many applied pharmacokineticists the prospect of conducting a Bayesian analysis will require numerous alien concepts to be taken on board and it may be difficult to justify investing the time and effort required in order to understand them (especially since the approach is so computer-intensive). For this reason we provide here a thorough (but often informal) discussion of all aspects of Bayesian inference as they apply specifically to population PK/PD. We also acknowledge that while the WinBUGS software is general purpose, model specification for some types of problem, population PK/PD being a prime example, can be very difficult, to the extent that a specialized interface for describing the problem at hand is often a practical necessity. In the latter part of this paper we describe such an interface, namely PKBugs. A principal aim of the paper is to offer sufficient technical background, in an easy to follow format, that the reader may develop both the confidence and know-how to make appropriate use of the PKBugs/WinBUGS framework (or similar software) for their own data analysis needs, should they choose to adopt a Bayesian approach.

Entities:  

Mesh:

Year:  2002        PMID: 12449499     DOI: 10.1023/a:1020206907668

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Software for population pharmacokinetics and pharmacodynamics.

Authors:  L Aarons
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

3.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

4.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

5.  A comparison of a Bayesian population method with two methods as implemented in commercially available software.

Authors:  J E Bennett; J C Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

6.  Population pharmacokinetics of gentamicin in neonates.

Authors:  A H Thomson; S Way; S M Bryson; E M McGovern; A W Kelman; B Whiting
Journal:  Dev Pharmacol Ther       Date:  1988

7.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

8.  Inter- and intra-subject variability of metoprolol kinetics after intravenous administration.

Authors:  J Richard; J M Cardot; J Godbillon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

9.  The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis.

Authors:  D J Lunn; L Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1998-02
  9 in total
  50 in total

1.  Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.

Authors:  Steven Kathman; Theingi M Thway; Lei Zhou; Stephanie Lee; Steven Yu; Mark Ma; Naren Chirmule; Vibha Jawa
Journal:  AAPS J       Date:  2016-01-19       Impact factor: 4.009

2.  Recommendations and proposed guidelines for assessing the cumulative evidence on joint effects of genes and environments on cancer occurrence in humans.

Authors:  Paolo Boffetta; Deborah M Winn; John P Ioannidis; Duncan C Thomas; Julian Little; George Davey Smith; Vincent J Cogliano; Stephen S Hecht; Daniela Seminara; Paolo Vineis; Muin J Khoury
Journal:  Int J Epidemiol       Date:  2012-05-16       Impact factor: 7.196

3.  The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Authors:  Lena E Friberg; Geoffrey K Isbister; L Peter Hackett; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Propagation of population pharmacokinetic information using a Bayesian approach: comparison with meta-analysis.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability.

Authors:  Aristides Dokoumetzidis; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12-12       Impact factor: 2.745

6.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

7.  Performance of an iterative two-stage bayesian technique for population pharmacokinetic analysis of rich data sets.

Authors:  Johannes H Proost; Douglas J Eleveld
Journal:  Pharm Res       Date:  2006-11-07       Impact factor: 4.200

Review 8.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

9.  Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.

Authors:  Tianli Wang; Kyle Baron; Wei Zhong; Richard Brundage; William Elmquist
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

10.  Simultaneous Bayesian inference for skew-normal semiparametric nonlinear mixed-effects models with covariate measurement errors.

Authors:  Yangxin Huang; Getachew A Dagne
Journal:  Bayesian Anal       Date:  2011-03-11       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.